Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Evotec, Fraunhofer in Drug Discovery Collaboration

Published: Tuesday, July 08, 2014
Last Updated: Tuesday, July 08, 2014
Bookmark and Share
The exclusive, strategic collaboration will combine the relevant platforms of both organisations, focusing on several disease areas.

Evotec AG announced today a collaboration with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME in several disease areas through the combination of the relevant platforms of both organisations for internal and external drug discovery projects. 

This alliance expands Evotec's already powerful drug discovery platform with access to a broad range of complementary and highly innovative platforms and capabilities to progress own innovate projects and provides additional capabilities for customers and partners of Evotec and IME, respectively. The deal follows the joint decision of Evotec, Fraunhofer-Gesellschaft and the City of Hamburg to integrate the European ScreeningPort GmbH into the IME thereby forming the first Fraunhofer life science institution in the City of Hamburg.

“We are looking forward to partner with Fraunhofer IME and are excited about the potential of this alliance. The IME has an impressive track record for product development and provides an ideal basis for collaborating with one of the strongest science organisations in Germany and beyond. This adds another footprint in Europe of our EVT Innovate programmes as we have with US based academic institutions,” Dr Werner Lanthaler, Chief Executive Officer of Evotec

“This collaboration constitutes a win-win situation through the project-specific combination of first-in-class capabilities. In particular, Evotec´s medicinal chemistry and expertise will add value to our own, our joint and our partner´s programmes. We look forward to collaborate with an experienced player in the life science industry on several layers now and in the future,” Prof. Dr Rainer Fischer, Senior Executive Director at the Fraunhofer IME.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Evotec and Padlock Therapeutics Extend Collaboration
Evotec and Padlock Therapeutics announce initial success and extension of long-term collaboration.
Friday, January 09, 2015
Evotec Receives Pre-Clinical Milestone with Boehringer Ingelheim
The milestone relates to the transition of an oncology molecule into pre-clinical development.
Tuesday, December 10, 2013
Evotec Enters Biology Collaboration with Probiodrug
Evotec will setup and validate assays to support the pre-clinical and clinical development of QC inhibitors in Alzheimer’s disease.
Thursday, November 29, 2012
Evotec Receives Pre-clinical Milestone Payment
Evotec AG announces that its research alliance with Boehringer Ingelheim has achieved a milestone triggering a payment of EUR 4 million to Evotec.
Friday, August 19, 2011
Evotec Starts Phase II Clinical Studies in Treatment-Resistant Depression
The proof-of-concept Phase II trial will study the safety and tolerability of EVT 101 while also exploring the efficacy of this intervention.
Thursday, July 01, 2010
Evotec Reports Progress in Product Development in Treatment-Resistant Depression in its Alliance with Roche
Company completion its first-in-man study with EVT 103 and receives a positive feedback from the FDA to initiate Phase II with EVT 101.
Thursday, March 11, 2010
Evotec Extends Medicinal Chemistry Collaboration with Ono Pharmaceutical
Ono to access Evotec’s ion channel drug discovery platform and expertise and Evotec to receive research funding and milestone payments.
Monday, October 19, 2009
Evotec Starts Phase I with EVT 103, an NR2B-selective NMDA Receptor Antagonist
EVT 103 is currently planned to enter clinical development for treatment-resistant depression in collaboration with Roche.
Wednesday, September 09, 2009
Evotec Announces the Successful Completion of the First Phase I Study with EVT 401
The double-blind, placebo controlled study showed that the compound was safe and well tolerated without any serious adverse events.
Friday, July 10, 2009
Evotec Acquires Zebrafish Screening Operations of Summit Corporation
The acquisition against £ 0.5 million cash in 2009 expected to add approximately £ 1.5 million revenues in 2010.
Friday, May 08, 2009
Evotec Reports Results of Phase II Proof-of-Concept Study with EVT 302
Study fails to demonstrate any significant improvement in the quit rate compared with placebo.
Monday, April 20, 2009
Evotec Presents its Fragment Screening Technology at Two Key Conferences
Presentations will be given at Screening, MedChem and ADMET Europe and at the Molecular Medicine Tri-Conference.
Thursday, February 19, 2009
Evotec Reports Phase I Safety Data from Tyramine Interaction Study with EVT 302
The study was undertaken to determine potential safety advantages of EVT 302 versus non-selective MAO inhibitors and less selective MAO-B inhibitors.
Monday, November 03, 2008
Evotec Announces Phase I Initiation with P2X7 Antagonist
P2X7 receptor antagonism may provide a novel approach to the treatment of rheumatoid arthritis and other inflammatory conditions.
Friday, October 10, 2008
Evotec’s EVT 101 Well Tolerated in Four Week Higher Repeat Dose Safety Study
The study showed in both young and elderly subjects that EVT 101 was well tolerated up to the highest dose tested.
Friday, July 04, 2008
Scientific News
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
Teeth Reveal Lifetime Exposures to Metals, Toxins
Researchers have identified dental biomarkers to reveal links between early iron exposure and late life brain diseases.
An Innovative Algorithm to Decipher How Drugs Work Inside the Body
Researchers at Columbia University Medical Center (CUMC) have developed a computer algorithm that is helping scientists see how drugs produce pharmacological effects inside the body.
Uncovering the Spread of Bacteria in Pneumonia
Northwestern Medicine scientists have discovered the role a toxin produced by a pneumonia-causing bacterium plays in the spread of infection from the lungs to the bloodstream in hospitalized patients.
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
Rare Form: Novel Structures Built from DNA Emerge
DNA, the molecular foundation of life, has new tricks up its sleeve. The four bases from which it is composed can be artificially manipulated to construct endlessly varied forms in two and three dimensions.
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!